Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05598632

Risk Factors for Stroke or Systemic Embolism in Chinese Patients with Non-Valvular Atrial Fibrillation Registry

Status
Recruiting
Phase
Study type
Observational
Enrollment
22,000 (estimated)
Sponsor
China National Center for Cardiovascular Diseases · Other Government
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

This study is aimed to validate the existing stroke risk stratification model for patients with atrial fibrillation (AF) (CHA2DS2-VASc Score, CHADS2 Score, ATRIA score, ABC score, etc.) and establish a new stroke risk assessment model using a nationwide AF -specific registry in China.

Detailed description

This study is a multicenter prospective disease-specific registry of patients with atrial fibrillation (AF) that will analyze factors that are associated with stroke or systemic embolic events in patients with AF in China. Approximately 5,000 prospective cohort of patients and 22,000 retrospective cohort of patients will be enrolled. Consecutive patients who meet the eligibility criteria and provide informed consent. Patients enrolled in the registry will be followed for approximately 3 years. Patient follow-up by National Center for Cardiovascular Diseases will continue as scheduled. Atrial Fibrillation Data capture will include demographics, cardiovascular risk factors, diagnosis, type of AF (paroxysmal, persistent, permanent AF), treatment strategy (rate vs. rhythm), antithrombotic therapy, concomitant medications and doses, laboratory tests, echo and computed tomography results, blood sample, insurance and provider information, comorbidities, and outcomes. The primary outcome will be stroke or non-CNS embolism. Other pre-defined outcomes of interest will include major adverse cardiac events, all-cause mortality, cause-specific death (sudden, non-sudden, heart failure-related), major bleeding, and hospitalization for heart failure.

Conditions

Timeline

Start date
2023-04-18
Primary completion
2024-12-31
Completion
2025-12-31
First posted
2022-10-28
Last updated
2024-11-06

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05598632. Inclusion in this directory is not an endorsement.